PD-1 Blockade-Mediated Rescue of Exhausted T Cells Requires CD28 [Immunotherapy]
PD-1 suppresses T cell activity by inhibiting the T cell costimulatory receptor CD28. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: Immunotherapy Source Type: research
T-cell Bispecific Antibodies Suppress Multiple Myeloma [Multiple Myeloma]
T-cell bispecific antibodies (TCB) targeting BCMA or FcRH5 induce T cell–mediated myeloma cell death. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: Multiple Myeloma Source Type: research
Rechallenge with BRAF and MEK Inhibitors Has Antitumor Activity [Clinical Trials]
Resistance to BRAF plus MEK inhibitors may be reversible in patients with BRAFV600-mutant melanoma. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: Clinical Trials Source Type: research
MK-8242 Is Active in Patients with p53 Wild-Type Advanced Solid Tumors [Clinical Trials]
The MDM2 inhibitor MK-8242 is tolerable in patients with liposarcoma and other advanced solid tumors. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: Clinical Trials Source Type: research
Targeting Class IIa HDACs May Suppress Breast Tumors and Metastases [Immunology]
Inhibition of class IIa HDACs with TMP195 promotes a macrophage-dependent reduction in tumor burden. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: Immunology Source Type: research
Converging on RAS [News in Depth]
Biologists at the Frederick National Laboratory for Cancer Research have teamed up with computer scientists and physicists at the Department of Energy to tackle the problem of "undruggable" RAS. The goal is to obtain a precise understanding of how RAS is activated by interactions with the plasma membrane; this will be illuminated through supercomputer simulations that build on structural and biochemical studies of RAS. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: News in Depth Source Type: research
Noted [News in Brief]
A collection of recently published news items. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Gut Microbes May Up PD-1 Inhibitor Response [News in Brief]
Confirming the results of animal studies, new research shows that the composition of patients' microbiome influences their response to checkpoint inhibitors. Patients with melanoma who benefit from PD-1 inhibitors carry a greater variety of species and higher numbers of microbes in the Clostridiales group. Increased abundance of certain bacteria in this group also correlated with higher numbers of CD8+ T cells in patients' tumors. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
$100M Africa Initiative Targets Childhood Cancer [News in Brief]
The Bristol-Myers Squibb Foundation have teamed up with Texas Children's Cancer and Hematology Centers and Baylor College of Medicine on a $100 million initiative to improve pediatric cancer care in sub-Saharan Africa. Organizers are partnering with local governments to increase access to specialty care in countries where the mortality rate from cancer in children is as high as 90%. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
iRECIST Guideline Unveiled for Immunotherapies [News in Brief]
The new iRECIST guideline—developed in consultation with academics, drug companies, and regulatory authorities—provides a standardized approach to assessing whether patients' disease improves, stays the same, or worsens in trials of immunotherapeutics, agents that can trigger different response patterns from other kinds of drugs. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Of Cancer and Random Mutations [News in Brief]
In an expanded analysis that includes data from 69 countries, researchers at Johns Hopkins School of Medicine in Baltimore, MD, once again report a strong correlation between stem-cell division rates and lifetime cancer risk. They have also calculated, for the first time, the respective contributions of random replication errors, environmental factors, and heredity to mutations that drive cancer. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
People [News in Brief]
William M. Anderson; Eric Fearon, MD, PhD; and Thomas J. Lynch Jr., MD, are featured. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
In This Issue [In This Issue]
(Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: In This Issue Source Type: research
The Bipartite Substrate Binding Site in MRP1 Recognizes Diverse Structures [Structural Biology]
The substrate binding site in MRP1 contains a positively charged region and a hydrophobic region. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: Structural Biology Source Type: research
Aryl Sulfonamides Target Pre-mRNA Splicing in Cancer [Splicing]
The anticancer sulfonamide indisulam inhibits protumorigenic pre-mRNA splicing. (Source: Cancer Discovery)
Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Tags: Splicing Source Type: research
